Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE2413.0036 (+1.51 %)

PREV CLOSE ( ) 2377.00

OPEN PRICE ( ) 2399.70

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 9833

TODAY'S LOW / HIGH ( )2327.85 2431.40

52 WK LOW / HIGH ( )1240.55 2531.95

NSE2414.5530.7 (+1.29 %)

PREV CLOSE( ) 2383.85

OPEN PRICE ( ) 2388.45

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 2414.55 (61)

VOLUME 364670

TODAY'S LOW / HIGH( ) 2324.45 2434.00

52 WK LOW / HIGH ( )1246.75 2540

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone 022-66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

Link Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE, MCX

NEWS

02May Announcement under Regulation 30 (LOD
NRC in its meeting held today allotted 1000 shares. Pls find attached en..

02May For Fixing Of Record Date In Relation
Record Date fixed for the Buy Back is 30th May 2024. Pls find enclosed R..

02May Pursuant To Regulation 30 Of SEBI (LO
Pls find enclosed details towards: 1. Appointment of Cost Auditors 2...

26Apr Buy Back Offer
Buy Back of Shares & Quarterly Results & Audited Results

15Apr Ajanta Pharma informs about compliance
Ajanta Pharma has informed that it enclosed Compliance Certificate - Reg..

Financials

Rs. in Millions

	QTR Mar 24	ANNUAL 24
Net Profit	1626.9	8072.40000000001
Gross Profit	2259.4	10969.5
Operating Profit	2608.3	12359.1
Net Sales	9260.7	39711.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE) 5154.90 (5.21%)	M.Cap ( in Cr)61634.56
Fredun Pharma (BSE) 981.65 (8.95%)	M.Cap ( in Cr)463.50
Caplin Point Lab (BSE) 1330.00 (2.40%)	M.Cap ( in Cr)10100.25
Pfizer (BSE) 4242.00 (0.71%)	M.Cap ( in Cr)19406.19
Lupin (BSE) 1679.75 (1.48%)	M.Cap ( in Cr)76828.07

Shareholding Pattern

	PROMOTERS	66.21%
	MUTUAL FUNDS/UTI	14.76%
	NON-INSTITUTION	7.76%
	FI/BANKS/INSURANCE	2.16%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	5.91
HDFC Pharma and Hea...	5.19
Aditya Birla SL Pha...	4.16
Kotak Healthcare Fu...	3.12
Nippon India Pharma...	3.03
Samco Active Moment...	3.00
Samco ELSS Tax Save...	2.62

Risk Disclosures on Derivatives

Smart Quotes

AJANTA PHARMA LTD.